Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson iNVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International operational growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2022
7.3%
Period ended Jan 1, 2023
Change on a year earlier
+1.9 pts
5.4% in FY2021
History
6 years
Since FY2017
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Jan 1, 2023 | 7.3% | +1.9 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | 5.4% | -12.2 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | 17.6% | -4.5 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | 22.1% | +20.8 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | 1.3% | -22.4 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | 23.7% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International operational growth YoY (%) (%), annual FY2017–FY2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_invokana_intl_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.